Rosiglitazone (BRL49653), a PPARγ-selective agonist, causes peroxisome proliferator-like liver effects in obese mice
Open Access
- 1 July 1999
- journal article
- research article
- Published by Elsevier in Journal of Lipid Research
- Vol. 40 (7) , 1177-1184
- https://doi.org/10.1016/s0022-2275(20)33479-9
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- PPARγ3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoterFEBS Letters, 1998
- PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.Diabetes, 1998
- Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δProceedings of the National Academy of Sciences, 1997
- The PPARα–leukotriene B4 pathway to inflammation controlNature, 1996
- Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat.Endocrinology, 1996
- 15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγCell, 1995
- Differential Activation of Peroxisome Proliferator-activated Receptors by EicosanoidsJournal of Biological Chemistry, 1995
- Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more…Chemistry & Biology, 1995
- mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.Genes & Development, 1994
- Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferatorsNature, 1990